DI
BCRX icon

Disciplined Investments’s BioCryst Pharmaceuticals BCRX Stock Holding History

Disciplined Investments’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-18
Closed -$127 – 254
2023
Q2 		$127 Buy
18
+11
+157% +$88 ﹤0.01% 1572
2023
Q1 		$58 Sell
7
-11
-61% -$106 ﹤0.01% 1622
2022
Q4 		$207 Sell
18
-2
-10% -$25 ﹤0.01% 1426
2022
Q3 		$0 Buy
20
+15
+300% +$193 ﹤0.01% 1237
2022
Q2 		$0 Sell
5
-7
-58% -$72 ﹤0.01% 1267
2022
Q1 		$0 Buy
+12
New +$192 ﹤0.01% 1341

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Disciplined Investments's BCRX Position: Q3 2023 in Review

Disciplined Investments sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2023, closing a stake of 18 shares — an estimated $127 sold.

Disciplined Investments first reported a position in BCRX in Q1 2022 and held it in 6 quarters. The position peaked at $207 in Q4 2022. 233 funds tracked by Wall St. Rank hold BCRX as of Q3 2023.

  • Disciplined Investments reported no remaining BioCryst Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Disciplined Investments sold 18 BioCryst Pharmaceuticals shares in Q3 2023, an estimated $127.
  • Disciplined Investments first reported a position in BioCryst Pharmaceuticals in Q1 2022 and held it in 6 quarters.
  • Disciplined Investments's BioCryst Pharmaceuticals position peaked at $207 in Q4 2022.
  • 233 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2023.

Based on Disciplined Investments's 13F filing for Q3 2023, filed 14 Nov 2023.